Shared on10 Aug 25Fair value Decreased 15%
The downward revision in the analyst price target for Treace Medical Concepts primarily reflects a material decline in the forecasted Future P/E multiple, while revenue growth expectations remain stable, resulting in a new fair value of $8.35. What's in the News Four-year interim results from the ALIGN3D multicenter study show the Lapiplasty® Procedure delivers sustained clinical and radiographic success for hallux valgus, including early return to weight bearing (average 7.7 days) and low recurrence rates (0.8% using HVA>20°, 8.4% using HVA>15° at 48 months).
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 1.87%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 16%
AnalystConsensusTarget has increased future PE multiple from 21.3x to 25.2x and decreased shares outstanding growth rate from 0.0% to 0.0%.
Shared on02 Apr 25Fair value Decreased 3.06%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.